Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | PHGDH | O43175 | 3/20 | 0.46 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275021 | 0.84 | CYP11B1 (0.57) | CYP11B1HSD11B1CYP11B2PDE10APHGDH | |
| SCHEMBL5025698 | 0.83 | MAPT (0.47) | CYP11B1HSD11B1CYP11B2KMT2AMAPT | |
| SCHEMBL27549688 | 0.82 | CYP11B1 (0.56) | CYP11B1HSD11B1CYP11B2PDE10APHGDH | |
| SCHEMBL11962167 | 0.81 | MEN1 (0.49) | CA9PHGDHKMT2AMAPTRAB9A | |
| SCHEMBL10246572 | 0.81 | CYP11B1 (0.55) | CYP11B1HSD11B1CYP11B2PDE10APLA2G7 | |
| SCHEMBL4903796 | 0.79 | CYP11B1 (0.56) | CYP11B1HSD11B1CYP11B2PDE10APHGDH | |
| SCHEMBL17069344 | 0.79 | CYP11B1 (0.54) | CYP11B1HSD11B1CYP11B2PDE10APHGDH | |
| SCHEMBL10190913 | 0.79 | CYP11B1 (0.54) | CYP11B1HSD11B1CYP11B2PDE10APHGDH | |
| SCHEMBL4685144 | 0.79 | TLR8 (0.42) | CYP11B1HSD11B1CYP11B2PLA2G7MGLL | |
| SCHEMBL15638677 | 0.77 | ADORA2A (0.43) | CYP11B1HSD11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023107552-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-10981879-B2 | Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-20 | — | — | US | disclosed |
| US-20190201404-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2019-07-04 | — | — | US | disclosed |
| US-10278972-B2 | Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2019-05-07 | — | — | US | disclosed |
| US-20190031623-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-01-31 | — | — | US | disclosed |
| EP-3191486-B1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2018-08-01 | — | — | EP | disclosed |
| US-9920075-B2 | Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170247343-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247396-A1 | TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170216293-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2017-08-03 | — | — | US | disclosed |
| US-9260395-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-02-16 | — | — | US | disclosed |
| US-9260395-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-02-16 | — | — | US | disclosed |
| US-20150274673-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | HIVIH (FR) | 2015-10-01 | — | — | US | disclosed |
| US-20150274673-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | HIVIH (FR) | 2015-10-01 | — | — | US | disclosed |
| US-20150274673-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | HIVIH (FR) | 2015-10-01 | — | — | US | disclosed |
| EP-2903969-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2015-08-12 | — | — | EP | disclosed |
| WO-2015097123-A1 | NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2015-07-02 | — | — | WO | disclosed |
| US-20150175623-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2015-06-25 | — | — | US | disclosed |
| EP-2886545-A1 | New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2015-06-24 | — | — | EP | disclosed |
| WO-2014053665-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216293-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TYMS, TYMP, TPX2 | CYP11B1 1542/4885HSD11B1 3767/4885CYP11B2 1284/4885 |
| US-20170247396-A1 | TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | CYP11B1 697/4885HSD11B1 1809/4885CYP11B2 918/4885 |
| US-20190031623-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | CYP11B1 628/4885HSD11B1 1174/4885CYP11B2 648/4885 |
| US-20170247343-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | CYP11B1 628/4885HSD11B1 1174/4885CYP11B2 648/4885 |
| US-10278972-B2 | Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | TYMS, TYMP, TPX2 | CYP11B1 1542/4885HSD11B1 3767/4885CYP11B2 1284/4885 |
| US-20150274673-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | RPL35, EIF2AK2, POLRMT | CYP11B1 1991/4885HSD11B1 2708/4885CYP11B2 2290/4885 |
| US-20190201404-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TYMS, TYMP, TPX2 | CYP11B1 1542/4885HSD11B1 3767/4885CYP11B2 1284/4885 |
| US-20150175623-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TYMS, TYMP, TPX2 | CYP11B1 1542/4885HSD11B1 3767/4885CYP11B2 1284/4885 |
| US-10981879-B2 | Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | CYP11B1 628/4885HSD11B1 1174/4885CYP11B2 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.